An efficient and stereoselective route to 1- deoxy- 5-hydroxy sphingosine analogues by saikia, P P et al.
Tetrahedron Letters 50 (2009) 1328–1330Contents lists available at ScienceDirect
Tetrahedron Letters
journal homepage: www.elsevier .com/ locate / tet letAn efﬁcient and stereoselective route to 1-deoxy-5-hydroxy
sphingosine analogues
Partha Pratim Saikia, Abhishek Goswami, Gakul Baishya, Nabin C. Barua *
Natural Products Chemistry Division, North East Institute of Science and Technology, Jorhat 785 006, India
a r t i c l e i n f o a b s t r a c tArticle history:
Received 20 November 2008
Revised 1 January 2009
Accepted 9 January 2009
Available online 13 January 2009
Keywords:
Sphingolipids
Asymmetric synthesis
Asymmetric Henry reaction
Hydrolytic kinetic resolution
Regioselective ring opening0040-4039/$ - see front matter  2009 Elsevier Ltd. A
doi:10.1016/j.tetlet.2009.01.024
* Corresponding author.
E-mail address: ncbarua12@rediffmail.com (N.C. BA short and efﬁcient synthesis of 1-deoxy-5-hydroxy sphingolipid is described. The key steps involved are
a Jacobsen hydrolytic kinetic resolution (HKR) and Shibasaki’s asymmetric Henry reaction.
 2009 Elsevier Ltd. All rights reserved.C13H27
OH OH
NH2
C13H27
OH OH
NH2
2
3
Sphingosine (1)
Safingol (4)
C13H27 OH
OH
NH2
C13H27
OH
OH
NH2
CH3
CH3
C4H9
OR
OR CH3 OH
OH OH
NH2Sphingolipids are ubiquitous components of cell membranes
that play critical roles in many physiological processes including
cell recognition, adhesion and signalling.1 Over the past decade,
signiﬁcant strides have been made in the elucidation of the biolog-
ical function of sphingolipids. One remarkable ﬁnding is the iden-
tiﬁcation of sphingolipid metabolites as second messengers, which
provides the basis for the emerging concept of sphingolipid metab-
olites as therapeutics with clinical potential.2 While the interest in
investigating the biological functions of sphingolipids grows, ef-
forts for the effective preparation of natural and nonnatural sphin-
golipids have generated much attention.3
This family of biomolecules has been shown to play a variety of
important roles in the chemistry of cellular membranes as well as
in cell growth, differentiation and apoptosis. For instance, the anti-
cancer activity of the parent D-erythro-(2S,3R)-sphingosine 1 and
other sphingolipids has been demonstrated both in vitro and
in vivo against colon cancer cell lines. However, it was observed
that sphingosine 1-phosphate produced in vivo from sphingosine
1 possessed promitotic and antiapoptotic properties. In order to
overcome this problem, Liotta et al.4 have developed 1-deoxy-5-
hydroxysphingosine analogues 2 and 3with C-2, C-3 amino alcohol
stereochemistry of saﬁngol 4. The primary hydroxyl group of
sphingosine has been moved to the C-5 position to maintain simi-
lar lipophilicity while further decreasing the opportunity for phos-
phorylation of hydroxyl substituents ( Fig. 1). The resulting 1-
deoxy-5-hydroxysphingosine analogue 2 has exhibited excellentll rights reserved.
arua).activity against colon cancer. Similar aminodiol stereochemistry
is also found in the substructure of fungal toxin fumonisin B1 5.
So far, only one synthesis of 2 has been reported in the literature.5
Over the past few years, investigations in our laboratory have
demonstrated the utility of nitroaliphatics in the synthesis of phar-
macologically important natural products.6 In this context, we re-
port herein our successful exercise towards the synthesis of 1-
deoxy-5-hydroxy sphingolipid 2.Fumonisin B1 (5) R = C(O)CH2CH(CO2H)CH2CO2H
Figure 1. 1-Deoxy-5-hydroxysphingolipid analogues and an aminodiol substruc-
ture containing natural products.
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Scheme 1. As indicated in the scheme, the nitro alcohol 15 could
serve as the key intermediate, which can be traced back to the pro-
tected alcohol 11, which in turn could be obtained from the epox-
ide 6a. We reasoned that the stereochemistry at C-5 could be
secured by the regioselective ring opening of the epoxide. For the
installation of the stereochemistry of the C-2 and C-3 stereocen-
tres, we relied on Shibasaki’s asymmetric Henry reaction.
The synthesis of the 1-deoxy-5-hydroxy sphingolipid analogue
(2) started from racemic 2-(2-benzyloxyethyl)-oxirane (6). Thus,
racemic 2-(2-benzyloxyethyl)-oxirane (6) was subjected to Jacob-
sen’s HKR7 using (S,S)-(salen)CoIIIOAc complex to give (S)-2-(2-
benzyloxyethyl)-oxirane8 (6a) as the optically pure isomer
(Scheme 2).
With enantiomerically pure 2-(2-benzyloxyethyl)-oxirane (6a)
in hand, we then subjected it to Li2CuCl4-catalysed9 regioselective
ring opening with dodecyl magnesium bromide to give the corre-
sponding alcohol 7 in 88% yield (Scheme 3). The hydroxyl protec-OBn
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Scheme 2. Reagents and conditions: (i) (S,S)-(salen)CoIIIOAc (0.5 mol %), distd. H2O
(0.55 equiv), 0 C, 14 h, (44% for 6a, 46% for 6b).
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Scheme 3. Reagents and conditions: (a) C12H25MgBr, Li2CuCl4, THF, 0 C; (b) Ac2O,
pyridine, rt; (c) H2, Pd–C, ethyl acetate; (d) Dess–Martin periodinane, CH2Cl2, 0 C;
(e) nitroethane, La-(R)-BINOL, THF, 40 C: (f) TBSOTf, 2,6-lutidine, CH2Cl2, 0 C; (g)
3 N HCl, THF, rt; (h) H2, Pd–C, EtOH.
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Scheme 1. Retrosynthetic analysis.tion of 7 with acetic anhydride in the presence of pyridine
furnished 8 in a quantitative yield. Compound 8 was then sub-
jected to Pd–C-catalysed hydrogenation to afford 9 in 92% yield.
Our next aim was to carry out the two-carbon homologation of
9 with the generation of the desired stereocentres by means of
Shibasaki’s asymmetric Henry reaction.10 To this end, compound
9 was oxidised to the aldehyde 10 with DMP in 94% yield. Then,
the aldehyde 10 was treated with nitroethane in the presence of
La-(R)-BINOL catalyst at 40 C, but under these reaction condi-
tions 10 was not stable and slowly decomposed without yielding
the nitroaldol product. Therefore, we decided to change the pro-
tecting group of the alcohol 7. Accordingly, treatment of 7 with
TBS triﬂate in the presence of 2,6-lutidine afforded 11 in 95% yield.
Removal of the benzyl protecting group in 11 released the terminal
hydroxyl group to furnish 12 in 85% yield. Oxidation of 12 with
DMP smoothly proceeded to produce the aldehyde 13. The alde-
hyde 13 without further puriﬁcation was subjected to Shibasaki’s
asymmetric nitroaldol reaction with nitroethane under the inﬂu-
ence of La-(R)-BINOL catalyst in THF at 40 C to deliver the nitro
alcohol 14 in 68% yield over two steps with a satisfactory diaste-
reomeric ratio (10:1; syn:anti).11 Desilylation of 14 with 3 N HCl
gave 15 in 73% yield. Finally, reduction of the nitro group in 15
with H2/Pd–C afforded the target compound 2 in 82% yield, the
spectral and physical data of which were identical to those
reported.5
In conclusion, we have demonstrated a new and ﬂexible syn-
thetic sequence for the preparation of 1-deoxy-5-hydroxy sphingo-
lipid analogues in 29% overall yield from chiral oxirane 6a. The
synthetic route detailed herein is potentially useful for the synthe-
sis of other natural products bearing similar aminodiol substruc-
tures. Moreover, this synthetic strategy is perceptibly efﬁcient for
tuning the stereochemistry at the C-2, C-3 and C-5 positions to ob-
tain different sphingolipid analogues.
Spectral data of selected compounds: Compound 6a: ½a20D 15.6 (c
1.26, CHCl3). IR (CHCl3): m = 3031, 2860, 1601, 1492, 1255,
1098 cm1. 1H NMR (300 MHz, CDCl3): d = 7.36–7.24 (m, 5H),
4.52 (s, 2H), 3.62 (t, 2H, J = 7.2 Hz), 3.07–3.01 (m, 1H), 2.79–2.76
(m, 1H), 2.53–2.52 (m, 1H), 1.96–1.86 (m, 1H), 1.82–1.76 (m,
1H). 13C NMR (75 MHz, CDCl3): d = 137.9, 128.1, 127.8, 127.3,
66.7, 49.8, 46.8, 32.6. MS (ESI): m/z = 179.0 (M++1). Compound 7:
½a20D +6.2 (c 0.8, CHCl3). IR (CHCl3): m = 3413, 2924, 2853 cm1. 1H
NMR (300 MHz, CDCl3): d = 7.33–7.26 (m, 5H), 4.52 (s, 2H), 3.79–
3.75 (m, 1H), 3.68–3.63 (m, 2H), 2.92 (br s, 1H), 1.75–1.73 (m,
2H), 1.49–1.42 (m, 2H), 1.25 (br s, 20H), 0.90 (t, 3H, J = 5.7 Hz).
13C NMR (75 MHz, CDCl3): d = 137.6, 128.1, 127.4, 127.3, 73.0,
71.2, 69.0, 37.1, 36.0, 31.6, 29.4, 29.0, 25.3, 22.4, 13.8. MS (ESI):
m/z = 372.0 (M++Na); Compound 11: ½a20D 7.1 (c 1.0, CHCl3). IR
(CHCl3): m = 2953, 2926, 2854, 1463 cm1. 1H NMR (300 MHz,
CDCl3): d = 7.31–7.25 (m, 5H), 4.46–4.45 (d, 2H, J = 3.0 Hz), 3.80–
3.78 (m, 1H), 3.50 (t, 2H, J = 6.0 Hz), 1.75–1.68 (m, 2H), 1.38–1.36
(m, 2H), 1.22 (br s, 22H), 0.86–0.84 (m, 12H), 0.01 (s, 3H), 0.00
(s, 3H). 13C NMR (75 MHz, CDCl3): d = 138.6, 128.3, 127.6, 127.5,
72.9, 69.4, 67.2, 37.6, 36.9, 31.9, 29.8, 29.74, 29.72, 29.6, 29.4,
25.9, 25.0, 22.7, 18.1, 14.1, 4.3, 4.5. MS (ESI): m/z = 485.1
(M++Na); Compound 12: ½a20D 14.6 (c 1.2, CHCl3). IR (CHCl3):
m = 3351, 2926, 2855, 1463, 1255 cm1. 1H NMR (300 MHz, CDCl3):
d = 3.82–3.80 (m, 2H), 3.63 (m, 1H), 2.45 (br s, 1H), 1.80–1.65 (m,
1H), 1.43–1.41 (m, 2H), 1.16 (br s, 24H), 0.80–0. 76 (m, 12H),
0.00 (s, 3H), 0.01 (s, 3H). 13C NMR (75 MHz, CDCl3): d = 72.1,
60.3, 37.5, 36.7, 31.9, 29.8, 29.7, 29.67, 29.63, 29.61, 29.4, 25.8,
25.3, 22.7, 17.9, 14.1, 4.4, 4.7. MS (ESI): m/z = 374.2 (M++2);
Compound 14: ½a20D 16.1 (c 1.04, CHCl3). IR (CHCl3): m = 3428,
2926, 2854, 1551 cm1. 1H NMR (300 MHz, CDCl3): d = 4.43–4.39
(m, 1H), 4.21–4.19 (m, 1H), 3.85–3.81 (m, 1H), 1.55–1.45 (m,
4H), 1.43 (d, 3H, J = 6.6 Hz), 1.17 (br s, 22H), 0.80–0.77 (m, 12H),
0.03 (s, 3H), 0.08 (s, 3H). 13C NMR (75 MHz, CDCl3): d = 87.8,
1330 P. P. Saikia et al. / Tetrahedron Letters 50 (2009) 1328–133070.1, 44.7, 37.8, 35.9, 31.9, 29.6, 29.5, 29.3, 25.7, 22.7, 17.9, 15.5,
14.1, 11.1, 3.9, 4.5. MS (ESI): m/z = 446.5 (M++1); Compound
15: mp 54–56 C. ½a20D 6.7 (c 0.9, CHCl3). IR (CHCl3): m = 3401,
2924, 2853, 1552 cm1. 1H NMR (300 MHz, CDCl3): d = 4.60–4.57
(m, 1H), 4.30–4.25 (m, 1H), 3.94–3.90 (m, 1H), 3.37 (br s, 2H),
1.69–1.58 (m, 4H), 1.55 (d, 3H, J = 6.3 Hz), 1.25 (br s, 22H), 0.90
(t, 3H, J = 6.0 Hz). 13C NMR (75 MHz, CDCl3): d = 70.4, 68.7, 37.5,
31.9, 29.6, 29.5, 29.3, 25.6, 22.7, 16.1, 14.1. MS (ESI): m/z = 354.2
(M++Na); Compound 2: mp 64–65 C. ½a20D +2.9 (c 0.8, CHCl3). IR
(CHCl3): m = 3400, 2920, 2848, 1474 cm1. 1H NMR (300 MHz,
CDCl3): d = 3.8 (m, 1H), 3.74 (m, 1H), 3.24 (br s, 4H), 2.81 (m,
1H), 1.6 (m, 1H), 1.45 (m, 3H), 1.25 (br s, 22H), 1.00 (d, 3H,
J = 6.2 Hz), 0.87 (t, 3H, J = 7.0 Hz). 13C NMR (75 MHz, CDCl3):
d = 76.5, 70.1, 52.3, 41.2, 35.5, 32.2, 29.82, 29.76, 29.6, 29.5, 25.8,
22.9, 17.4, 14.2. MS (ESI): m/z = 324.4 (M++Na).
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